Gene · 9180
OSMR: oncostatin M receptor
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. OSMR: oncostatin M receptor. Genes, record 9180. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/9180
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q99650 | Oncostatin-M-specific receptor subunit beta | 979 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents157
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 56531 | Q99650 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 2896 | Q99650 | Espacenet |
| EP 4640849 A2 | 2025-10-29 | 358 | Q99650 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 2461 | Q99650 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 9857 | Q99650 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 16772 | Q99650 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 3300 | Q99650 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 7241 | Q99650 | Espacenet |
| JP 2025114801 A | 2025-08-05 | 1 | Q99650 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 3300 | Q99650 | Espacenet |
1 to 10 of 157
See all 157 patentsDrugs1
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action |
|---|---|---|---|
| VIXARELIMAB | CHEMBL4594341 | Oncostatin-M-specific receptor subunit beta inhibitor | INHIBITOR |
Source ChEMBL
Trials5
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT06693908 | VIXARELIMAB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT06137183 | VIXARELIMAB | PHASE2 | 2026-02-24 | ClinicalTrials.gov |
| NCT05785624 | VIXARELIMAB | PHASE2 | ClinicalTrials.gov | |
| NCT03858634 | VIXARELIMAB | PHASE2 | 2021-12-28 | ClinicalTrials.gov |
| NCT03816891 | VIXARELIMAB | PHASE2 | 2026-01-13 | ClinicalTrials.gov |
NIH grants973
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | OSMR papers | Newest fiscal year |
|---|---|---|---|
| P20GM103408 | Idaho INBRE Program | 12 | 2025 |
| P30CA016056 | Roswell Park Cancer Center Support Grant | 7 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 7 | 2025 |
| T32CA059366 | Cancer Biology Training Grant | 6 | 2025 |
| P30CA034196 | Cancer Center Support (CORE) Grant | 3 | 2025 |
| P30CA043703 | Case Comprehensive Cancer Center Support Grant | 3 | 2025 |
| P30DK043351 | Center for the Study of Inflammatory Bowel Disease at Massachusetts General Hospital | 3 | 2025 |
| R01AI051321 | Structure-based engineering of immune cytokine signaling | 3 | 2025 |
| U01DK062422 | Mount Sinai NYC Genetics Research Center: Multi-omic integration across data-types, cell niches and populations | 3 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 3 | 2025 |
1 to 10 of 973Source NIH's project files
See all 973 nih grantsPapers1,423
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Lipid Metabolic Dysregulation Driven by OSMR Mutations Underlies Amyloidogenesis in Primary Localized Cutaneous Amyloidosis. | Adv Sci (Weinh) | 2026 | 42811488 | PubTator, text mining | PubMed |
| The Role of the OSM/OSMRβ Axis in Chronic Liver Disease Progression and Hepatocellular Carcinoma Development: A Focus on MASLD/MASH. | Int J Mol Sci | 2026 | 42794644 | PubTator, text mining | PubMed |
| Oncostatin M as a Multifunctional Regulator of Breast Cancer Progression: Current Insights and Future Therapeutic Avenues. | IUBMB Life | 2026 | 42746957 | PubTator, text mining | PubMed |
| : Interleukin-31 in Atopic Dermatitis and Prurigo Nodularis: Pathophysiology, Neuroimmune Mechanisms, and Clinical Efficacy of Nemolizumab. | J Drugs Dermatol | 2026 | 42696343 | PubTator, text mining | PubMed |
| Identification of Glioblastoma Cell Surface Proteins and Assessment of Their Expression Across Patient-Derived Stem-Like Cell Cultures. | J Proteome Res | 2026 | 42695909 | PubTator, text mining | PubMed |
| Tape Strip Transcriptomics Reveal Nemolizumab Effects on Pruritus, Hyperplasia, Inflammation, and Extracellular Matrix Markers in Patients With Moderate-to-Severe Atopic Dermatitis. | Allergy | 2026 | 42693785 | PubTator, text mining | PubMed |
| Autosomal recessive OSMRβ deficiency: Connecting OSM and/or IL-31 with atopy. | J Hum Immun | 2026 | 42639505 | PubTator, text mining | PubMed |
| Cryo-EM structure of the interleukin-31 receptor complex defines non-canonical interactions that confer receptor specificity. | J Biol Chem | 2026 | 42637078 | PubTator, text mining | PubMed |
| KLF4 in Smooth Muscle Cell-Derived Progenitor Cells Is Essential for Angiotensin II-Induced Cardiac Inflammation and Fibrosis. | Arterioscler Thromb Vasc Biol | 2026 | 42619593 | PubTator, text mining | PubMed |
| Longitudinal transcriptomic analysis of mucosa in ulcerative colitis after anti-tumor necrosis factor withdrawal compared to continued treatment. | J Crohns Colitis | 2026 | 42586604 | PubTator, text mining | PubMed |
1 to 10 of 1,423
See all 1,423 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/9180
GET https://conductscience.org/api/genes/v1/9180/patents?page=2